3-Iodobenzylguanidine
-
Subject Areas on Research
- (4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
- 1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation.
- 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
- A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
- A kit method for the high level synthesis of [211At]MABG.
- A radioiodinated MIBG-octreotate conjugate exhibiting enhanced uptake and retention in SSTR2-expressing tumor cells.
- Abnormalities of cardiac sympathetic function in pacing-induced heart failure as assessed by [123I]metaiodobenzylguanidine scintigraphy.
- Biological evaluation of ring- and side-chain-substituted m-iodobenzylguanidine analogues.
- Carcinoid tumors: iodine-131 MIBG scintigraphy.
- Carrier-free 131I-meta-iodobenzylguanidine: comparison of production from meta-diazobenzylguanidine and from meta-trimethylsilylbenzylguanidine.
- Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells.
- Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
- Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group.
- Detecting pheochromocytoma: defining the most sensitive test.
- Effect of mild hyperglycemia +/- meta-iodo-benzylguanidine on the radiation response of R3230 Ac tumors.
- Effects of specific activity on meta-[(131)I]iodobenzylguanidine kinetics in isolated rat heart.
- Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
- Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model.
- Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma.
- Factors controlling oxygen utilization.
- Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
- Iodine 131-labeled metaiodobenzylguanidine scintigraphy and biochemical analyses in suspected pheochromocytoma.
- Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity.
- Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.
- Iodine-131-metaiodobenzylguanidine uptake in metastatic carcinoid tumor to the orbit.
- Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguanidine.
- Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity.
- Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG.
- MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
- MIBG inhibits respiration: potential for radio- and hyperthermic sensitization.
- MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis.
- Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.
- Meta-[211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent.
- Meta-iodobenzylguanidine and analogues: chemistry and biology.
- Meta-iodobenzylguanidine derivatives containing a second guanidine moiety.
- Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia.
- New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment.
- No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
- No-carrier-added meta-[123I]iodobenzylguanidine: synthesis and preliminary evaluation.
- No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue.
- No-carrier-added synthesis of meta-[131I]iodobenzylguanidine.
- Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
- Phase-1 clinical trial results of high-specific-activity carrier-free 123I-iobenguane.
- Platelet uptake of the pheochromocytoma-scanning agent 131I-meta-iodobenzylguanadine.
- Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG.
- Radioiodinated O(6)-Benzylguanine derivatives containing an azido function.
- Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors.
- Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.
- Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG.
- Synthesis of carrier-free 131I-meta-iodobenzyl-guanidine by novel routes to enhance therapeutic efficiency in neuroblastoma.
- Synthesis of ring- and side-chain-substituted m-iodobenzylguanidine analogues.
- The impact of minimally invasive parathyroidectomy on the way endocrinologists treat primary hyperparathyroidism.
- Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.
- Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart.
- Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG.
- Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.
- Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.
- Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.